source
- Biohaven's ataxia drug resubmission accepted by FDA, shares surge 36%Biohaven’s experimental drug troriluzole, being developed for spinocerebellar ataxia, was previously rejected by the FDA because the agency questioned the design of the registrational trial. The co…
- Medrio aims to unify clinical trial tools to ease complexity for biotech firmsMike Novotny, founder and CEO of Medrio, says that funding cycles, growing study complexity and fragmented technology are slowing clinical research, especially for small and midsize life‑science co…